A research team headed by a professor from Virginia Commonwealth University has succeeded in improving a method used for determining the charge, size and shape of water-soluble molecules. Joseph Reiner, Department of Physics, Assistant professor of experimental nanoscience in the College of Humanities and Sciences and his co-workers have enumerated their discovery in an article "Enhanced Single Molecule Mass Spectrometry Via Charged Metallic Clusters," to be published in the Analytical Chemistry journal.
Titan Spine, a medical device surface technology company focused on developing innovative spinal interbody fusion implants, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its Endoskeleton® line of interbody fusion implants featuring its next-generation nanoLOCKTM surface technology.
Arcturus Therapeutics, Inc., a leading RNA medicines company pursuing orphan diseases, today announced it will present a poster at the 2nd International mRNA Health Conference being held on November 11-12, 2014 in Cambridge, MA.
EnGeneIC, Ltd., an emerging biopharmaceutical company focused on developing its proprietary EDV™ nanocell platform for the targeted delivery of cancer therapeutics and other therapeutic molecules, announced today that, together with the Asbestos Disease Research Institute (ADRI), it has initiated the first clinical trial evaluating its bacterially-derived and antibody-guided EDV™ nanocells packaged with microRNA for the treatment of patients with malignant pleural mesothelioma (MPM).
Researchers at the Max Planck Institute for Intelligent Systems have developed nanoscale swimming bodies which are able to navigate through complicated biological fluids.
With medical and security professionals in the U.S. and across the world searching for a quick, portable and effective way to screen for the Ebola virus, an American medical device company is seeking funding for emerging technology that could screen for Ebola and a host of diseases within minutes, simply by testing an individual's breath.
BIND Therapeutics, Inc., a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, today announced a joint research and development agreement with Merck, known as MSD outside the United States and Canada, through a subsidiary, to discover and develop novel nanomedicines for oncology.
Novavax, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, announced today that representatives of Novavax, along with a number of its research collaborators, will be making multiple oral presentations and poster presentations related to Novavax' RSV F-protein nanoparticle vaccine candidate (RSV F Vaccine) at the 9th International Respiratory Syncytial Virus Symposium to be held November 9 – 13, 2014 in Stellenbosch, South Africa.
Artificial platelet mimics developed by a research team from Case Western Reserve University and University of California, Santa Barbara, are able to halt bleeding in mouse models 65 percent faster than nature can on its own.
Researchers at the University of Missouri-Kansas City School of Pharmacy have developed a novel mucoadhesive hyaluronic acid (HA) nanofibre delivery system which could help to prevent the transmission of HIV.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.